Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High...

Area of Science:

• Pediatric Oncology
• Hematology
• Molecular Biology

Background:

• Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a rare and poorly understood subtype.
• Understanding the clinical and genetic landscape of pediatric γδ T-ALL is crucial for improving outcomes.

Purpose of the Study:

• To investigate the clinical features, genetic drivers, and therapeutic vulnerabilities of pediatric γδ T-ALL.
• To establish a risk stratification framework for this disease.

Main Methods:

• Analysis of clinical and genetic data from 200 pediatric γδ T-ALL patients.
• Functional studies using patient samples and isogenic cell lines to explore STAG2 inactivation.
• High-throughput drug screening to identify therapeutic targets.

Main Results:

• Age and genetic drivers significantly impact patient outcomes.
• γδ T-ALL in children under 3 years old is extremely high-risk, associated with LMO2 activation and STAG2 inactivation.
• STAG2 inactivation disrupts chromatin organization, affecting gene expression and T-cell differentiation.
• Drug screening revealed a vulnerability in DNA repair pathways actionable by poly(ADP-ribose) polymerase (PARP) inhibitors.

Conclusions:

• A diagnostic and risk stratification framework for pediatric γδ T-ALL is proposed.
• Young age (<3 years) and high end-induction measurable residual disease (≥1%) define high-risk disease.
• STAG2 inactivation presents a therapeutic vulnerability targetable by PARP inhibition.